A look at the U.S. Food and Drug Administration’s drug approval review calendar.

The U.S. Food and Drug Administration approved Incyte’s Pemazyre (pemigatinib), a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test.

With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.